Pharmacological |
Principal Investigator | |
ALECARDIO: A multicenter, randomized, double blind, placebocontrolled cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome event and type 2 diabetes |
Giora Weisz, MD |
|
|
